LOS ANGELES, June 02, 2024--Puma Biotechnology announced that findings from the Phase II trial of its drug alisertib (TBCRC 041) were presented at the ASCO 2024 Annual Meeting.
LOS ANGELES, May 28, 2024--Puma Biotechnology is on the preliminary list of additions to the Russell 3000 Index.
Key Insights Given the large stake in the stock by institutions, Puma Biotechnology's stock price might be vulnerable...